MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 540077 | Name: Ciprofibrate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ciprofibrate is a PPARα agonist used to decrease levels of triglycerides and total cholesterol and increase levels of HDL. It also induces depolarization of the mitochondrial membrane potential and enhances peroxisome proliferation.

Chemical Structure

Ciprofibrate
Ciprofibrate
CAS#52214-84-3

Theoretical Analysis

MedKoo Cat#: 540077

Name: Ciprofibrate

CAS#: 52214-84-3

Chemical Formula: C13H14Cl2O3

Exact Mass: 288.0300

Molecular Weight: 289.15

Elemental Analysis: C, 54.00; H, 4.88; Cl, 24.52; O, 16.60

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 Weeks
2g USD 350.00 2 Weeks
5g USD 650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
BRN 1984981; BRN1984981; BRN-1984981; CCRIS 173; CCRIS173; CCRIS-173; Ciprofibrate; (±)-Ciprofibrate; WIN 35833; WIN35833; WIN-35833
IUPAC/Chemical Name
2-(4-(2,2-dichlorocyclopropyl)phenoxy)-2-methylpropanoic acid
InChi Key
KPSRODZRAIWAKH-UHFFFAOYSA-N
InChi Code
InChI=1S/C13H14Cl2O3/c1-12(2,11(16)17)18-9-5-3-8(4-6-9)10-7-13(10,14)15/h3-6,10H,7H2,1-2H3,(H,16,17)
SMILES Code
CC(C)(OC1=CC=C(C2C(Cl)(Cl)C2)C=C1)C(O)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 289.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Heydel JM, Garnier P, Faure P, Artur Y. Ciprofibrate regulation of rat hepatic bilirubin glucuronidation and UDP-glucuronosyltransferases expression. Eur J Drug Metab Pharmacokinet. 2012 Dec;37(4):233-40. doi: 10.1007/s13318-012-0091-z. Epub 2012 Apr 4. PubMed PMID: 22476862. 2: Shah D, Mavani D, Patel H, Baldania S, Bhatt K, Chhalotiya U. Development and validation of liquid chromatography-tandem mass spectrometric method for the quantification of ciprofibrate from human plasma. J Chromatogr Sci. 2015 Feb;53(2):219-25. doi: 10.1093/chromsci/bmu043. Epub 2014 May 15. PubMed PMID: 24833347. 3: Mendes FD, Chen LS, Borges A, Babadópulos T, Ilha JO, Alkharfy KM, Mendes GD, De Nucci G. Ciprofibrate quantification in human plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry for pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Aug 15;879(24):2361-8. doi: 10.1016/j.jchromb.2011.05.055. Epub 2011 Jun 12. PubMed PMID: 21763220. 4: Domingos H, Cunha RV, Paniago AM, Souza AS, Rodrigues RL, Domingos JA. Rosuvastatin and ciprofibrate in the treatment of dyslipidemia in patients with HIV. Arq Bras Cardiol. 2012 Nov;99(5):997-1007. Epub 2012 Oct 30. English, Portuguese. PubMed PMID: 23108642. 5: Bighetti EJ, Patrício PR, Casquero AC, Berti JA, Oliveira HC. Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver. Lipids Health Dis. 2009 Nov 23;8:50. doi: 10.1186/1476-511X-8-50. PubMed PMID: 19930639; PubMed Central PMCID: PMC2784759. 6: dos Santos AG, Guardia AC, Pereira TS, Ataíde EC, Mei Md, Udo ME, Boin IF, Stucchi RS. Rhabdomyolysis as a clinical manifestation of association with ciprofibrate, sirolimus, cyclosporine, and pegylated interferon-α in liver-transplanted patients: a case report and literature review. Transplant Proc. 2014 Jul-Aug;46(6):1887-8. doi: 10.1016/j.transproceed.2014.05.065. Review. PubMed PMID: 25131061. 7: Mountassif D, Kabine M, Mounchid K, Mounaji K, Latruffe N, El Kebbaj MS. Sensitivity of liver metabolism in jerboa (Jaculus orientalis) to ciprofibrate, a peroxisome proliferator. Mol Med Rep. 2009 Jul-Aug;2(4):597-602. doi: 10.3892/mmr_00000143. PubMed PMID: 21475872. 8: Hierlihy AM, Cooke GM, Curran IH, Mehta R, Karamanos L, Price CA. Effects of ciprofibrate on testicular and adrenal steroidogenic enzymes in the rat. Reprod Toxicol. 2006 Jul;22(1):37-43. Epub 2005 Dec 7. PubMed PMID: 16337773. 9: Martinsen TC, Bakke I, Chen D, Sandvik AK, Zahlsen K, Aamo T, Waldum HL. Ciprofibrate stimulates the gastrin-producing cell by acting luminally on antral PPAR-alpha. Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G1052-60. Epub 2005 Aug 11. PubMed PMID: 16099866. 10: Bermúdez-Pirela V, Souki A, Cano-Ponce C, Bermúdez-Arias F, Mengual-Moreno E, Leal-Gonzalez E, Lemus-Antepaz M, de Bravo MC, de Díaz AA, de Pirela NL, Cano-Peñaloza R, Puche-Medina G, Arraiz N, Reyna-Villazmil N, Contreras F, Israili ZH, Valasco M. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype. Am J Ther. 2007 Mar-Apr;14(2):213-20. PubMed PMID: 17414592. 11: Lupp A, Karge E, Danz M, Deufel T, Oelschläger H, Klinger W. Single and chronic administration of ciprofibrate or of ciprofibrate-glycinate in male Fischer 344 rats: comparison of the effects on morphological and biochemical parameters in liver and blood. Eur J Drug Metab Pharmacokinet. 2005 Jul-Sep;30(3):203-18. PubMed PMID: 16250258. 12: Fidaleo M, Sartori C. Administration of ciprofibrate to lactating mothers induces PPARalpha-signaling pathway in the liver and kidney of suckling rats. Exp Toxicol Pathol. 2008 Jun;60(1):33-41. doi: 10.1016/j.etp.2007.12.002. Epub 2008 Apr 22. PubMed PMID: 18434116. 13: Paragh G, Seres I, Harangi M, Erdei A, Audikovszky M, Debreczeni L, Kovácsay A, Illyés L, Pados G. Ciprofibrate increases paraoxonase activity in patients with metabolic syndrome. Br J Clin Pharmacol. 2006 Jun;61(6):694-701. PubMed PMID: 16722831; PubMed Central PMCID: PMC1885110. 14: Lupp A, Karge E, Deufel T, Oelschlägers H, Fleck C. Ciprofibrate, clofibric acid and respective glycinate derivatives. Effects of a four-week treatment on male lean and obese Zucker rats. Arzneimittelforschung. 2008;58(5):225-41. doi: 10.1055/s-0031-1296499. PubMed PMID: 18589557. 15: Tharappel JC, Nalca A, Owens AB, Ghabrial L, Konz EC, Glauert HP, Spear BT. Cell proliferation and apoptosis are altered in mice deficient in the NF-kappaB p50 subunit after treatment with the peroxisome proliferator ciprofibrate. Toxicol Sci. 2003 Oct;75(2):300-8. Epub 2003 Jul 25. PubMed PMID: 12883078. 16: Jain PS, Jivani HN, Khatal RN, Surana SJ. Quantitative Determination of Ciprofibrate in Tablets by Derivative UV Spectroscopy and RP-HPLC Method. Indian J Pharm Sci. 2012 Mar;74(2):168-71. doi: 10.4103/0250-474X.103855. PubMed PMID: 23326000; PubMed Central PMCID: PMC3546336. 17: Yadetie F, Laegreid A, Bakke I, Kusnierczyk W, Komorowski J, Waldum HL, Sandvik AK. Liver gene expression in rats in response to the peroxisome proliferator-activated receptor-alpha agonist ciprofibrate. Physiol Genomics. 2003 Sep 29;15(1):9-19. PubMed PMID: 12851464. 18: Gatica A, Aguilera MC, Contador D, Loyola G, Pinto CO, Amigo L, Tichauer JE, Zanlungo S, Bronfman M. P450 CYP2C epoxygenase and CYP4A omega-hydroxylase mediate ciprofibrate-induced PPARalpha-dependent peroxisomal proliferation. J Lipid Res. 2007 Apr;48(4):924-34. Epub 2007 Jan 17. PubMed PMID: 17234604. 19: Vicentini FC, Elisa Ravanini A, Silva TA, Janegitz BC, Zucolotto V, Fatibello-Filho O. A novel architecture based upon multi-walled carbon nanotubes and ionic liquid to improve the electroanalytical detection of ciprofibrate. Analyst. 2014 Aug 21;139(16):3961-7. doi: 10.1039/c4an00861h. PubMed PMID: 24919542. 20: Kovács I, Toldy E, Abel T, Tarján J, Császár A. The effect of ciprofibrate on flow-mediated dilation and inflammatory markers in patients with combined hyperlipidemia. Endothelium. 2005 Jul-Aug;12(4):179-83. PubMed PMID: 16162440.